Opinion

Video

Future Perspectives on the Treatment of NSCLC

Author(s):

Edgardo S. Santos, MD, FACP, FCCP

Dr Edgardo Santos highlights key takeaways from the presented data and provides insights into how these findings could shape the future landscape of healthcare directions.

This is a video synopsis/ summary of an OncLive Insights® featuring Edgardo S. Santos, MD, FACP, FCCP.

In conclusion, Santos summarized key lung cancer advances from the 2023 World Conference on Lung Cancer and the European Society of Medical Oncology Congress. He covered data on new targeted therapies such as the HER2 antibody-drug conjugate trastuzumab deruxtecan and datopotamab deruxtecan for molecularly selected patients with non–small cell lung cancer. Beyond targets, combination approaches are ongoing, including antibody-drug conjugates with immunotherapy. However, developing effective regimens for immunotherapy-refractory lung cancer remains an unmet need. Santos expressed optimism that new treatment options are on the horizon for patients with lung cancer, both with and without targetable genomic alterations.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.

Related Videos
Benjamin Levy, MD
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
Lorlatinib vs Crizotinib in Treatment-Naive Patients With Advanced ALK+ Non-Small Cell Lung Cancer: 5-Year Progression-Free Survival and Safety From the CROWN Study
Chinmay Jani, MD, clinical fellow, Hematology & Oncology, Sylvester Comprehensive Cancer Center at the University of Miami/Jackson Memorial Hospital
Video 8 - 2 KOLs featured in , "Q&A: Final Questions on Glioblastoma and Neuroimaging"
Video 7 - 2 KOLs featured in, "Implementing PET RANO 1.0 Response Criteria in Glioblastoma Assessment "
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
A panel of 3 experts on breast cancer
Related Content
FDA
June 17th 2024

FDA Places Partial Clinical Hold on Phase 1 Trial of YL202 in Advanced NSCLC and Breast Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Eric Vallieres, MD, FRCSC, of Swedish Medical Center
June 13th 2024

A Surgeon’s Perspective: How to Optimize Outcomes With Neoadjuvant Chemo/IO in Lung Cancer

Hari B. Keshava, MD
October 23rd 2023

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

Fabrice Barlesi, MD, PhD
June 10th 2024

Adjuvant Alectinib Approved in Europe for ALK+ Early-Stage NSCLC

FDA
June 10th 2024

FDA Grants Priority Review to Osimertinib for EGFR+ Stage III NSCLC